Moreover, trastuzumab deruxtecan has demonstrated a high intracranial response rate in patients with active brain metastases from HER2+ BC in the TUXEDO-1 trial (NCT04752059, EudraCT 2020-000981-41) [231]. This evidence concerns the gene ERBB2 and breast cancer.